BIOMARIN PHARMACEUTICAL INC Cash and Cash Equivalents, Period Increase (Decrease)
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$70.76 million for the 9-month period ending 2019-09-30, per its 10-Q/A filed 2019-11-04.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-11-04
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $115.64M, a 74.57% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$56.79M.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$129.61M.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$388.20M, a 332.97% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$104.05M, a 154.85% decline from fiscal 2017.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was $189.70M, a 1580.23% increase from fiscal 2016.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was $11.29M.
- BIOMARIN PHARMACEUTICAL INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$478.45M, a 256.00% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-09-30 | $115.64M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $58.85M derived: sum of 2 quarters · filed 2019-11-04 | -$70.76M 10-Q/A · filed 2019-11-04 | -$458.96M derived: sum of 4 quarters · filed 2019-11-04 |
| 2019-06-30 | -$56.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$186.41M 10-Q · filed 2019-08-02 | -$574.61M derived: sum of 3 quarters · filed 2019-08-02 | -$119.83M derived: sum of 4 quarters · filed 2019-11-04 |
| 2019-03-31 | -$129.61M 10-Q · filed 2019-04-29 | -$517.82M derived: sum of 2 quarters · filed 2019-04-29 | -$63.04M derived: sum of 3 quarters · filed 2019-11-04 | -$109.61M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-12-31 | -$388.20M derived: 10-K 12 month − 10-Q/A 9 month · filed 2019-02-28 | $66.57M derived: sum of 2 quarters · filed 2019-11-04 | $20.00M derived: sum of 3 quarters · filed 2019-11-04 | -$104.05M 10-K · filed 2019-02-28 |
| 2018-09-30 | $454.77M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $408.20M derived: sum of 2 quarters · filed 2019-11-04 | $284.16M 10-Q/A · filed 2019-11-04 | $450.79M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$46.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$170.62M 10-Q · filed 2019-08-02 | -$3.99M derived: sum of 3 quarters · filed 2019-08-02 | $72.55M derived: sum of 4 quarters · filed 2019-08-02 |
| 2018-03-31 | -$124.05M 10-Q · filed 2019-04-29 | $42.58M derived: sum of 2 quarters · filed 2019-04-29 | $119.12M derived: sum of 3 quarters · filed 2019-04-29 | $125.75M derived: sum of 4 quarters · filed 2019-04-29 |
| 2017-12-31 | $166.63M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $243.16M derived: sum of 2 quarters · filed 2019-02-28 | $249.79M derived: sum of 3 quarters · filed 2019-02-28 | $189.70M 10-K · filed 2019-02-28 |
| 2017-09-30 | $76.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $83.17M derived: sum of 2 quarters · filed 2018-10-26 | $23.07M 10-Q · filed 2018-10-26 | -$275.95M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | -$53.47M 10-Q · filed 2018-08-03 | -$352.49M derived: sum of 3 quarters · filed 2019-02-28 | $48.90M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$60.10M 10-Q · filed 2018-04-27 | -$359.12M derived: sum of 2 quarters · filed 2019-02-28 | $42.27M derived: sum of 3 quarters · filed 2019-02-28 | $77.78M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | -$299.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $102.36M derived: sum of 2 quarters · filed 2019-02-28 | $137.88M derived: sum of 3 quarters · filed 2019-02-28 | $11.29M 10-K · filed 2019-02-28 |
| 2016-09-30 | $401.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $436.90M derived: sum of 2 quarters · filed 2017-10-31 | $310.31M 10-Q · filed 2017-10-31 | $331.00M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $35.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$91.07M 10-Q · filed 2017-08-02 | -$70.38M derived: sum of 3 quarters · filed 2018-02-26 | -$134.69M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | -$126.59M 10-Q · filed 2017-05-04 | -$105.89M derived: sum of 2 quarters · filed 2018-02-26 | -$170.21M derived: sum of 3 quarters · filed 2018-02-26 | -$630.12M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $20.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | -$43.62M derived: sum of 2 quarters · filed 2018-02-26 | -$503.53M derived: sum of 3 quarters · filed 2018-02-26 | -$478.45M 10-K · filed 2018-02-26 |
| 2015-09-30 | -$64.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$524.22M derived: sum of 2 quarters · filed 2016-11-03 | -$499.14M 10-Q · filed 2016-11-03 | -$21.66M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | -$459.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$434.82M 10-Q · filed 2016-08-08 | $42.66M derived: sum of 3 quarters · filed 2017-02-27 | -$144.05M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $25.08M 10-Q · filed 2016-05-02 | $502.56M derived: sum of 2 quarters · filed 2017-02-27 | $315.85M derived: sum of 3 quarters · filed 2017-02-27 | $260.79M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $477.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $290.77M derived: sum of 2 quarters · filed 2017-02-27 | $235.71M derived: sum of 3 quarters · filed 2017-02-27 | $306.70M 10-K · filed 2017-02-27 |
| 2014-09-30 | -$186.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$241.77M derived: sum of 2 quarters · filed 2015-11-02 | -$170.78M 10-Q · filed 2015-11-02 | $216.44M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$55.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $15.94M 10-Q · filed 2015-08-05 | $403.15M derived: sum of 3 quarters · filed 2016-02-29 | $409.27M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $71.00M 10-Q · filed 2015-05-05 | $458.21M derived: sum of 2 quarters · filed 2016-02-29 | $464.33M derived: sum of 3 quarters · filed 2016-02-29 | $485.40M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $387.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $393.34M derived: sum of 2 quarters · filed 2016-02-29 | $414.40M derived: sum of 3 quarters · filed 2016-02-29 | $388.25M 10-K · filed 2016-02-29 |
| 2013-09-30 | $6.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $27.18M derived: sum of 2 quarters · filed 2014-10-28 | $1.04M 10-Q · filed 2014-10-28 | $235.00K derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $21.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$5.08M 10-Q · filed 2014-07-31 | -$5.88M derived: sum of 3 quarters · filed 2015-03-02 | -$2.31M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | -$26.15M 10-Q · filed 2014-05-02 | -$26.95M derived: sum of 2 quarters · filed 2015-03-02 | -$23.38M derived: sum of 3 quarters · filed 2015-03-02 | $71.79M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | -$803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $2.77M derived: sum of 2 quarters · filed 2015-03-02 | $97.94M derived: sum of 3 quarters · filed 2015-03-02 | $134.25M 10-K · filed 2015-03-02 |
| 2012-09-30 | $3.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $98.74M derived: sum of 2 quarters · filed 2013-10-28 | $135.06M 10-Q · filed 2013-10-28 | $110.08M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-06-30 | $95.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $131.49M 10-Q · filed 2013-07-29 | $106.50M derived: sum of 3 quarters · filed 2014-02-26 | $64.80M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-03-31 | $36.31M 10-Q · filed 2013-04-29 | $11.33M derived: sum of 2 quarters · filed 2014-02-26 | -$30.37M derived: sum of 3 quarters · filed 2014-02-26 | -$8.20M derived: sum of 4 quarters · filed 2014-02-26 |
| 2011-12-31 | -$24.98M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | -$66.68M derived: sum of 2 quarters · filed 2014-02-26 | -$44.51M derived: sum of 3 quarters · filed 2014-02-26 | -$41.81M 10-K · filed 2014-02-26 |
| 2011-09-30 | -$41.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-29 | -$19.53M derived: sum of 2 quarters · filed 2012-10-29 | -$16.82M 10-Q · filed 2012-10-29 | -$56.28M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $22.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $24.88M 10-Q · filed 2012-08-02 | -$14.58M derived: sum of 3 quarters · filed 2013-02-26 | -$2.82M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $2.70M 10-Q · filed 2012-04-30 | -$36.76M derived: sum of 2 quarters · filed 2013-02-26 | -$25.00M derived: sum of 3 quarters · filed 2013-02-26 | -$18.18M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | -$39.46M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$27.70M derived: sum of 2 quarters · filed 2013-02-26 | -$20.88M derived: sum of 3 quarters · filed 2013-02-26 | -$79.09M 10-K · filed 2013-02-26 |
| 2010-09-30 | $11.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $18.58M derived: sum of 2 quarters · filed 2011-10-31 | -$39.63M 10-Q · filed 2011-10-31 | -$64.24M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-01 | -$51.39M 10-Q · filed 2011-08-01 | -$76.00M derived: sum of 3 quarters · filed 2012-02-22 | -$84.27M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | -$58.21M 10-Q · filed 2011-04-29 | -$82.81M derived: sum of 2 quarters · filed 2012-02-22 | -$91.09M derived: sum of 3 quarters · filed 2012-02-22 | |
| 2009-12-31 | -$24.61M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$32.88M derived: sum of 2 quarters · filed 2012-02-22 | -$55.73M 10-K · filed 2012-02-22 | |
| 2009-09-30 | -$8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | -$31.12M 10-Q · filed 2010-10-29 | ||
| 2009-06-30 | -$22.85M 10-Q · filed 2010-08-04 | |||
| 2008-12-31 | -$5.44M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |